ClinicalTrials.gg
Not yet recruitingNCT07668180Updated Jun 25, 2026

A Study to Evaluate the Efficacy and Safety of IN-207907 Injection in Elderly Patients With Sarcopenia

A Phase 2 interventional study of IN-207907 120 mg and IN-207907 240 mg in Sarcopenia in Elderly, sponsored by HK inno.N Corporation. Not yet recruiting. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by HK inno.N Corporation · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to learn if intervention can treat sarcopenia in the elderly. Researchers will compare IN-207907 120 mg, 240 mg, 360 mg and placebo to see if SPPB score improves.

02

Conditions studied

  • Sarcopenia in Elderly

Browse trials for

03

In context

Sarcopenia

1,331 studies on the registry are indexed under Sarcopenia; 419 are open to participants now.

This study's planned enrollment of 100 is above the median of 60 across 857 interventional studies indexed under Sarcopenia.

Browse Sarcopenia studies →

Lead sponsor

HK inno.N Corporation is the lead sponsor of 104 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects aged ≥ 65 years (for female subjects, those who are medically unable to become pregnant)
  • Subjects diagnosed with sarcopenia in accordance with the Korean Working Group on Sarcopenia (KWGS) guidelines
  • Subjects with a body weight of ≥ 35 kg and a (BMI) of ≥ 15 kg/m² and \< 30 kg/m²
  • Subjects with a nutritional status screening score of ≥ 8 as assessed by the Mini Nutritional Assessment (MNA) questionnaire

Exclusion criteria

Exclusion Criteria:

  • Subjects with a history of diseases or surgical procedures that may affect physical activity or function
  • Subjects with underlying muscle disorders, including myopathy or muscular atrophy
  • Subjects with neuromuscular or neurological disorders
  • Subjects with uncontrolled diabetes mellitus, severe renal impairment, uncontrolled thyroid disorders, vitamin D deficiency, severe hepatic impairment, severe cardiac disease, uncontrolled hypertension, respiratory disorders
  • Subjects with findings on a 12-lead (ECG)
  • Subjects who are positive for active , active , syphilis, or
  • Subjects with a history of within 5 years
  • Subjects who have received systemic or immunostimulants
  • Subjects who have undergone treatment with plasmapheresis within 8 weeks
  • Subjects who have received treatment with medications prohibited in this clinical trial within 4 weeks
  • Subjects with levels \< 10 g/dL
  • Subjects who have undergone surgery requiring general anesthesia within 4 weeks
  • Subjects who are unable to walk or are physically inactive
  • Subjects who are participating in or planning to participate in a separate high-intensity program for increasing muscle mass or strength during the clinical trial period
  • Subjects with severe psychiatric disorders such as major depression, schizophrenia, alcoholism, or drug dependence
  • Subjects with a score of \< 24 on the Korean version of the (MMSE-K)
  • Subjects with known allergies or to the product or its
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    IN-207907 120 mg

    Drug: IN-207907 120 mg

  • Experimental
    IN-207907 240 mg

    Drug: IN-207907 240 mg

  • Experimental
    IN-207907 360 mg

    Drug: IN-207907 360 mg

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugIN-207907 120 mg

    IN-207907 120 mg will be administered by intravenous injection at 4-week intervals for a total of 3 doses.

  • DrugIN-207907 240 mg

    IN-207907 240 mg will be administered by intravenous injection at 4-week intervals for a total of 3 doses.

  • DrugIN-207907 360 mg

    IN-207907 360 mg will be administered by intravenous injection at 4-week intervals for a total of 3 doses.

  • DrugPlacebo

    Placebo will be administered by intravenous injection at 4-week intervals for a total of 3 doses.

06

What researchers measure

Primary outcomes

  1. Change in the Short Physical Performance Battery (SPPB) total score

    Range 0-12, higher scores indicate better physical performance

    Time frame: From baseline to week 12

Secondary outcomes

  1. Change in the Short Physical Performance Battery (SPPB) total score

    Range 0-12, higher scores indicate better physical performance

    Time frame: From baseline to week 4 and 8

  2. Change in time to complete the 4-Meter Walk Test (4MWT)

    Measured in seconds, lower values indicate better performance

    Time frame: From baseline to week 4, 8 and 12

  3. Change in time to complete the 5 Times Chair Stand Test

    Measured in seconds, lower values indicate better performance

    Time frame: From baseline to week 4, 8 and 12

  4. Change in time to complete the Timed Up and Go (TUG) test

    Measured in seconds, lower values indicate better performance

    Time frame: From baseline to week 4, 8 and 12

  5. Change in handgrip strength measured using a digital hand dynamometer

    In kilograms, higher values indicate greater muscle strength

    Time frame: From baseline to week 4, 8 and 12

  6. Change in Appendicular Skeletal muscle Mass (ASM) as measured by Dual-energy X-ray Absorptiometry (DEXA)

    Time frame: From baseline to week 12

  7. Change in the total score of the Strength, Assistance with walking, Rise from a chair, Climb stairs, and Falls (SARC-F) questionnaire

    Range 0-10; higher scores indicate worse sarcopenia risk

    Time frame: From baseline to week 12

  8. Change in the total score of the Sarcopenia Quality of Life (SarQoL) questionnaire

    Range 0-100, higher scores indicate better quality of life

    Time frame: From baseline to week 12

  9. Change in proportion of FoxP3+ regulatory T cells

    Measured as %

    Time frame: From baseline to week 4, 8 and 12

  10. Change in serum interleukin-6 (IL-6) concentration

    Measured in pg/mL

    Time frame: From baseline to week 4, 8 and 12

  11. Change in serum insulin-like growth factor-1 (IGF-1) concentration

    Measured in ng/mL

    Time frame: From baseline to week 4, 8 and 12

  12. Change in high-sensitivity C-reactive protein (hs-CRP) level

    Measured in mg/L

    Time frame: From baseline to week 4, 8 and 12

  13. Exercise and dietary compliance rate

    Time frame: From baseline to week 4, 8 and 12

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Feb 2028, 17 months later.

Of 20 phase 2 interventional studies under Sarcopenia, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's planned 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2026
First posted
Jun 25, 2026
StartEst.
Sep 2026
Primary completionEst.
Feb 2028
CompletionEst.
Feb 2028
Last update
Jun 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07668180
Responsible party
Sponsor
First posted
Jun 25, 2026
Start date
Sep 2026 (estimated)
Primary completion
Feb 2028 (estimated)
Completion
Feb 2028 (estimated)
Last update
Jun 25, 2026

Study contacts

Yujin Choi
Contact
yujin.choi@inno-n.com
+82 31-5176-4668
Ahrong Kim
Contact
ahrong.kim@inno-n.com
+82 31-5176-4666
Jae-Young Lim
principal investigator · Seoul National University Bundang Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion